Clinical Trial Update: A Study to Assess the Effect of Ticagrelor in Reducing the Number of Days With Pain in Patients With Sickle Cell Disease [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating ticagrelor to reduce pain days in sickle cell disease has completed with results posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sickle Cell Disease

Drugs mentioned

• TICAGRELOR (ticagrelor)

Snippet

Sponsor: AstraZeneca | Conditions: Sickle Cell Disease | Phase 2 | Status: COMPLETED | Results posted: 2017-12-14